SG11202102930YA - Interleukin 10 conjugates and uses thereof - Google Patents

Interleukin 10 conjugates and uses thereof

Info

Publication number
SG11202102930YA
SG11202102930YA SG11202102930YA SG11202102930YA SG11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA
Authority
SG
Singapore
Prior art keywords
conjugates
interleukin
Prior art date
Application number
SG11202102930YA
Inventor
Carolina E Caffaro
Jerod Ptacin
Marcos Milla
Original Assignee
Synthorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthorx Inc filed Critical Synthorx Inc
Publication of SG11202102930YA publication Critical patent/SG11202102930YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG11202102930YA 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof SG11202102930YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862757690P 2018-11-08 2018-11-08
US201962911036P 2019-10-04 2019-10-04
PCT/US2019/060261 WO2020097325A1 (en) 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11202102930YA true SG11202102930YA (en) 2021-04-29

Family

ID=70612119

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102930YA SG11202102930YA (en) 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof

Country Status (16)

Country Link
US (1) US20210338829A1 (en)
EP (1) EP3876973A4 (en)
JP (1) JP2022506531A (en)
KR (1) KR20210091170A (en)
CN (1) CN113260374A (en)
AU (1) AU2019376076A1 (en)
BR (1) BR112021005401A2 (en)
CA (1) CA3117572A1 (en)
CO (1) CO2021003530A2 (en)
IL (1) IL282736A (en)
MA (1) MA54195A (en)
MX (1) MX2021005293A (en)
PH (1) PH12021550611A1 (en)
SG (1) SG11202102930YA (en)
TW (1) TW202031284A (en)
WO (1) WO2020097325A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ761430A (en) 2017-08-03 2024-03-22 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
JP2021514974A (en) 2018-02-26 2021-06-17 シンソークス， インコーポレイテッド IL-15 conjugate and its use
BR112021014415A2 (en) 2019-02-06 2021-09-21 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USING THEM
CH716227B1 (en) * 2020-04-16 2020-11-30 Contrad Swiss Sa Gel composition for topical application for the reduction of local inflammation.
KR20230129423A (en) * 2020-12-09 2023-09-08 애셔 바이오테라퓨틱스, 인크. Fusion of antigen-binding molecules and mutant interleukin-10 polypeptide to regulate immune cell function
CN112618699A (en) * 2020-12-31 2021-04-09 深圳先进技术研究院 Reagent capable of providing interleukin 10 with effective treatment amount and antitumor application thereof
CA3222899A1 (en) * 2021-07-29 2023-02-02 Jinwei Yang Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
AU2004227937B2 (en) * 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
WO2013130913A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
CA2914837A1 (en) * 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3341012A4 (en) * 2015-08-25 2019-03-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2022512746A (en) * 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use

Also Published As

Publication number Publication date
KR20210091170A (en) 2021-07-21
AU2019376076A1 (en) 2021-04-15
CN113260374A (en) 2021-08-13
BR112021005401A2 (en) 2021-06-29
US20210338829A1 (en) 2021-11-04
MA54195A (en) 2022-02-16
IL282736A (en) 2021-06-30
PH12021550611A1 (en) 2021-10-04
EP3876973A4 (en) 2022-08-03
CA3117572A1 (en) 2020-05-14
TW202031284A (en) 2020-09-01
JP2022506531A (en) 2022-01-17
EP3876973A1 (en) 2021-09-15
WO2020097325A1 (en) 2020-05-14
MX2021005293A (en) 2021-06-23
CO2021003530A2 (en) 2021-04-19

Similar Documents

Publication Publication Date Title
EP3854806A4 (en) Novel interleukin 2 and use thereof
IL279897A (en) Fusosome compositions and uses thereof
IL276827A (en) Il-15 conjugates and uses thereof
SG11202011015QA (en) Fusosome compositions and uses thereof
IL282736A (en) Interleukin 10 conjugates and uses thereof
IL281192A (en) Interleukin-2 polypeptide conjugates and their uses
EP3854805A4 (en) Novel interleukin 2 and use thereof
IL290141A (en) Anti-pvrig antibodies formulations and uses thereof
IL279755A (en) Senolytic compositions and uses thereof
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL286847A (en) Hsp90-binding conjugates and formulations thereof
IL277791A (en) Hsp90-targeting conjugates and formulations thereof
IL283942A (en) Tubulysins and protein-tubulysin conjugates
ZA202005144B (en) Parenteral formulations and uses thereof
IL290301A (en) Il-15 conjugates and uses thereof
IL277663A (en) Erenumab compositions and uses thereof
GB201807576D0 (en) Compositions and uses thereof
SG11202009242RA (en) Short conjugated oligoelectrolytes and uses thereof
GB201821138D0 (en) Compositions and uses thereof
GB201812334D0 (en) Compositions and uses thereof
GB201821144D0 (en) Compositions and uses thereof
GB201819493D0 (en) Compositions and uses thereof
GB201818495D0 (en) Compositions and uses thereof
GB201818375D0 (en) Compositions and uses thereof
GB201815546D0 (en) Composition and uses thereof